Fort Lauderdale, FL, July 10, 2025 – PRISM MediaWire – SS Innovations International, Inc. (the "Company" or "SS Innovations") (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced the successful completion of the world's first robotic telesurgery for weight loss utilizing the Company's advanced SSi Mantra 3 surgical robotic system. This landmark bariatric telesurgery bridged a distance of ...

Led by Dr. Mohit Bhandari, a pioneer in bariatric surgery and President of the Institute of Research Against Digestive Cancer (IRCAD) India, the surgery was remotely performed at a distance of 560 miles and executed on-site at Mohak Bariatric & Robotic Surgery Centre in Indore, India.Two advanced One-Anastomosis Gastric Bypass (OAGB) procedures were performed via telesurgery, with zero perceptible lag, flawless precision, and seamless robotic control using the SSI Mantra 3 system. FORT LAUDERDALE, Fla., Jul ...

Company Overview - SS Innovations International, Inc. is a developer of innovative surgical robotic technologies aimed at making robotic surgery affordable and accessible globally [3] - The company is headquartered in India and plans to expand its global presence with user-friendly and cost-effective surgical robotic solutions [3] Recent Developments - The first robotic cardiac surgery in the Americas was successfully performed using the SSi Mantra 3 surgical robotic system on June 8, 2025, by Dr. Juan Zuniga in Guayaquil, Ecuador [1] - The procedure involved a robotic Atrial Septal Defect closure, which repairs a hole between the upper two chambers of the heart [1] Technology Features - The SSi Mantra surgical robotic system is a modular, multi-arm system featuring advanced technology such as 3 to 5 robotic arms, a 3D 4K monitor, and a touch panel for patient information [4] - It utilizes over 40 different types of robotic endo-surgical instruments to support various specialties, including cardiac surgery [4] - The system has been clinically validated in India for over 100 different types of surgical procedures [4] Surgical Experience - Dr. Zuniga reported that the SSi Mantra system was easy to handle, resulting in effective outcomes and faster recovery for patients due to its minimally invasive nature [2] - The precision of the robotic system enhances the surgeon's confidence in performing sutures and tissue manipulation [2] Hospital Adoption - Interhospital in Guayaquil is the first hospital in South America to install the SSi Mantra system and has utilized it for various complex surgical procedures since its installation [2]

One former Intuitive Surgical fan thinks it's time to sell the stock.Intuitive Surgical (ISRG -5.44%), the maker of surgical robots and tools for robotic surgery, is taking it on the chin in afternoon trading Monday. Through 2:22 p.m. ET, Intuitive stock has lost 5.5% of its value.You can blame Deutsche Bank for that. What Deutsche says about Intuitive SurgicalDeutsche Bank downgraded Intuitive Surgical stock to "sell" this morning, with a $440 price target implying more than 16% downside."Intuitive's da Vi ...

Press release Ecully, June 6, 2025 – 6.00 p.m. SPINEWAY Minutes of the General Meeting of June 4, 2025 The Combined General Meeting (Ordinary and Extraordinary) of Spineway shareholders was held on first notice on Wednesday, June 4, 2025 at 2:00 p.m at the company’s registered office, 7 allée Moulin Berger in Ecully (69). The defaulting shareholders were represented by SELARL TULIER POLGE ALIREZAI, as ad hoc representative appointed by Order of the President of the Lyon Commercial Court dated April 30, 2 ...

Noble Capital Markets Emerging Growth Virtual Equity Conference June 2025 Forward Looking Statement & Disclosures Except for specific historical information, many of the matters discussed in this presentation may express or imply projections of revenues or expenditures, statements of plans and objectives or future operations or statements of future economic performance. These statements may discuss goals, intentions and expectations as to future trends, plans, events, results of operations or financial cond ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style ...

Company Information - Spineway is engaged in the design, manufacture, and marketing of innovative implants and surgical instruments for treating severe spinal disorders [7] - The company has an international network of over 50 independent distributors, with more than 70% of its revenue generated from exports [7] Upcoming Events - A Combined General Meeting is scheduled for June 4, 2025, at 2:00 p.m. at the Group's headquarters in Ecully [3] - The notice of the meeting, including the agenda and resolutions, was published on April 30, 2025 [4] - The next financial report, detailing H1 2025 revenue, is expected on July 30, 2025 [5] Regulatory Information - Spineway is eligible for PEA-SME (Equity Savings Plans for SMEs), which may attract certain investors [6] - All preparatory documents for the General Meeting can be accessed on the company's website under "Investors/Regulated Information" [5]

Record Quarterly Revenue of $5.1 Million Driven by Higher SSi Mantra 3 Unit SalesOn Track for July 2025 De Novo Application to the FDA for SSi Mantra 3 FORT LAUDERDALE, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three months ended Mar ...

Core Insights - SS Innovations International, Inc. plans to submit a De Novo Classification Request to the FDA for the SSi Mantra 3 surgical robotic system in July 2025, aiming to enhance market access in the U.S. [1][2] Company Overview - SS Innovations is focused on developing innovative surgical robotic technologies to make robotic surgery affordable and accessible globally [6]. - The company has already marketed its SSi Mantra surgical robotic system in six countries and is pursuing further global expansion [5]. Product Performance - Since the launch of the SSi Mantra system in August 2022, 80 systems have been installed in 75 hospitals, with over 3,800 surgeries performed, including more than 200 robotic cardiac surgeries [3]. - The SSi Mantra 3 version, launched in June 2024, has seen 37 installations and over 750 multispecialty robotic surgical procedures, including 70 cardiac cases, with no device-related mortality or complications reported [3][4]. Clinical Validation - Real-world clinical data, validated by a leading contract research organization, supports the safety and efficacy of the SSi Mantra 3 for a variety of surgical procedures [4]. - The planned FDA submission will include applications for multispecialty indications such as urology, gynecology, general surgery, and thoracic and cardiac surgery [4]. Technological Features - The SSi Mantra Surgical Robotic System features a modular design with 3 to 5 robotic arms, an ergonomic surgeon command center, and advanced imaging capabilities, including a large 3D 4K monitor [7]. - It utilizes over 40 different types of robotic endo-surgical instruments to support various specialties, including cardiac surgery [7].